Document is current

Article History

Received: 25 May 2024

Accepted: 25 February 2025

First Online: 21 March 2025

Declarations

:

: For this retrospective analysis we used an institutional research database at the University Hospitals of Leuven, containing information on patients with mesenchymal tumors (LECTOR, reference number S51495), after obtaining ethics approval from our institutional ethics committee: Research Ethics Committee UZ/KU Leuven (reference number MP024913). The Committee confirms that they work in accordance with the ICH-GCP principles (International Conference on Harmonisation Guidelines on Good Clinical Practice), with the most recent version of the Helsinki Declaration, and with applicable laws and regulations. Informed consent from individual participants was deemed unnecessary according to this framework.

: Not applicable.

: PS has a consulting or advisory role at Ellipses Pharma, Deciphere, Transgene, Exelixis, Boehringer Ingelheim, Studiecentrum voor Kernenergie, Adcendo, PharmaMar, Merck Healthcare KGaA, Medpace, Cogent Biosciences, Eisai, Curio Science, LLX Solutions, SERVIER, Genmab, Sanofi, Regeneron, Moleculin Biotech, Avacta Life Sciences, Amryt Pharma, UCB, Boxer Capital, NEC OncoImmunity AS, Sonata Therapeutics, IDRx, Telix Pharmaceuticals. He received research funding from CoBioRes NV, Eisai, G1 Therapeutics, PharmaMar, Genmab, Merck, Sartar Therapeutics, ONA Therapeutics, Adcendo.The other authors declare that they have no competing interests.